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ABSTRAK
Tujuan: meneliti perbedaan imunoekspresi BRAF V600E di antara stadium Dukes pada karsinoma kolorektal. 
Metode: penelitian ini retrospektif, potong lintang, terhadap kasus karsinoma kolorektal masing-masing stadium 
Dukes A, B dan C sebanyak 15 kasus. Dilakukan pewarnaaan antibodi BRAF V600E terhadap potongan tipis 
massa tumor untuk mengevaluasi adanya protein BRAF V600E. Perbedaan proporsi imunoekspresi BRAF 
V600E di antara masing-masing stadium Dukes pada karsinoma kolorektal diuji menggunakan uji Chi-Square. 
Hasil: hasil pewarnaan imunohistokimia yang positif (positif sedang sampai positif kuat) pada stadium Dukes 
A, B, C adalah sebagai berikut: 1 kasus dari 15, 4 kasus dari 15 kasus dan 13 kasus dari 15 kasus. Pewarnaan 
imunohistokimia BRAF V600E yang positif lebih banyak ditemukan pada stadium Dukes C dan sangat bermakna 
(p<0,001) berdasarkan uji statistik Chi-Square. Kesimpulan: hasil pewarnaan imunohistokimia BRAF V600E 
dapat dipakai sebagai petanda karsinoma kolorektal yang lebih agresif.
Kata kunci: BRAF V600E, Dukes, imunoekspresi, karsinoma kolorektal.
ABSTRACT
Aim: to compare the immunoexpression of BRAF V600E among stage of colorectal cancer. Methods: this 
was a cross sectional, and retrospective study involving Dukes’ stage A, B, and C colorectal carcinoma, each 
with 15 cases. Immunohistochemistry was performed in paraffin-embedded specimens of tumor mass for the 
assessment of BRAF V600E. The proportion differences of immunoexpression of BRAF V600E among Dukes’stage 
A, B, and C were tested using Chi-Square test. Results: the result of positive BRAF V600E immunoexpression 
(moderately to strongly positive) in Dukes’stage A, B, and C were found in 1 of 15 cases, 4 of 15 cases and 13 of 
15 cases respectively. BRAF V600E immunoexpression was statistically significant more frequent in Dukes’stage 
C (p<0,001, Chi-Square test). Conclusion: positive BRAF V600E immunoexpression could be used as a marker 
of aggresive colorectal carcinoma.
Key words: BRAF V600E, Dukes, immunoexpression, colorectal carcinoma.
INTRODUCTION
Colorectal carcinoma (CRC) is the term for 
colon or rectum malignant epithelial tumor.1 
Colorectal cancer (CRC) is an important global 
health problem.2 Cancers of the colon and rectum 
are the third most common type worldwide.3
Colon cancer stage is the most important 
factor in predicting patient outcomes.4 First 
staging classification-Dukes’ stage is stage A, 
B, C, in which stage A tumours were confined 
to the rectal wall, stage B tumours breached 
extra-rectal tissues, and stage C tumours 
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had metastasised to lymph nodes. Treatment 
decisions are usually made in accordance with 
older Dukes classification schema. Primary 
colorectal carcinoma (CRC) treatment is 
surgery to remove the primary tumor. Adjuvant 
chemotherapy is a standard of care in stage III 
or Dukes’ stage C patients while its role is less 
well established in stage II or Dukes’ stage B.5,6 
Hence, other criteria for adjuvant therapy are 
needed. Molecular markers might prove to be 
better than clinical and histopathological criteria 
for therapy selection.7
The Ras/Raf/MEK/ERK mitogen-activated 
protein kinase (MAPK) pathway is a critical 
signal transduction pathway involved in many 
cancers, including colorectal cancer, and has 
been the target of therapeutic intervention in 
recent years.8 Critical to progress are molecular 
tests identifying the underlying genetic causes 
of dysregulated cell proliferation, such as certain 
BRAF gene mutations causing constitutive 
MAPK signaling and transcription-mediated 
cell division and survival. Recently, BRAF 
mutation testing has been introduced into routine 
clinical laboratories because its role has become 
clearer in terms of effect on pathogenesis of 
CRC.9 Ninety percent of BRAF mutations are 
accounted for by a thymine to adenine single-
base change at position 1,799. This missense 
mutation, located in exon 15, results in a change 
at residue 600 that substitutes glutamine for 
valine (V600E).10 The encoded protein has 
more than 10 times more kinase activity than 
its normal counterpart. Thus, BRAF V600E acts 
as an oncogene.9 Activating mutations in BRAF 
have been reported in 5–15% of CRC.11
Currently, only molecular methods, such 
as polimerase chain reaction (PCR), and 
various sequencing technologies are available 
for assessing BRAF mutational status. Thus, 
analysis is limited to high complexity molecular 
testing facilities, requiring specialized equipment 
and proficient personnel. This can increase cost 
and turn-around time, affecting patient care. 
Immunohistochemistry is available routinely 
in most pathology laboratories and, frequently, 
at a lower cost.12 An immunohistochemical 
approach for assessing BRAF V600E mutation 
in colorectal cancer and its relationship to 
Dukes’stage are evaluated to determine BRAF 
V600E status in colorectal cancer.
METHODS
This was cross sectional, retrospective study. 
We included Dukes’ stage A, B, and C colorectal 
carcinoma each with 15 archival paraffin blocks 
of tumor mass at Department of Anatomical 
Pathology, Hasan Sadikin Hospital, Bandung, 
from 2011-2012 for immunohistochemistry 
staining. We chose the case by consecutive 
sampling method. This study was conducted 
with human ethics review committee approval.
Immunohistochemistry
All hematoxylin-eosin (H+E) cases were 
reviewed for Dukes’stage and one representative 
block of each tumor was selected, 4µm sections 
were cut, and immunohistochemistry was 
performed using the anti BRAF V600E antibody 
VE1(Spring Bioscience). The generation 
and validation of this antibody have been 
reported previously.12 We used Labeled 
Streptavidin Avidin Biotin (LSAB) technique 
for immunohistochemical analysis.
The slides were heated in a 38oC oven for 
30 min, deparaffinized in three changes of 
xylene for 5 min each, rehydrated in graded 
alcohols (90%, 80%, and 70%) for 5 min each, 
and rinsed in deionized water. Antigen retrieval 
was performed in sodium citrat buffer 10mM in 
a pressure cooker (BioCare Medical, Concord, 
CA) for 30 min. The slides were rinsed in 
deionized water, rinsed in phosphate buffer 
saline (PBS) pH 7,2, applied blocking serum 
for 10 min, rinsed in PBS. The primary antibody 
(BRAF V600E, clone VE1, Spring Bioscience) 
was applied for overnight at room temperature at 
a 1:200 dilution. The sections were gently rinsed 
in PBSx2 for 5 min each. Secondary antibody 
Trekkie universal link (Biocare Medical) was 
applied for 20 min and rinsed in PBSx2 for 5 min 
each. The sections were labeled by TrekAvidin 
(HRP) for 10 min and rinsed in PBS x2 for 5 min 
each. Antigen detection was performed using 
the Betazoid DAB as the chromogen. The slides 
were counterstained with hematoxylin Mayer for 
2 minutes. The sections were gently rinsed in 
deionized water. The sections were dehydrated 
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in graded alcohols (70%, 80,% and 96%), cleared 
in xylene, and coverslipped. Positive controls 
were thyroid papillary carcinoma and negative 
controls were provided by omitting the primary 
antibody.
All H+E, and BRAF V600E-immunostained 
slides were reviewed by three pathologists 
independently (BSH, AHH, SS). The intensity 
of cytoplasmic tumor cell staining and the 
percentage of tumor cells stained were assessed. 
Slides that have different result interpretation 
were then viewed by these observers together 
to reach agreement on any discordant scores.
Scoring System
The expression of BRAF V600E was 
observed in the cytoplasm of tumor cells (Figure 
1–4). Immunoexpression was judged on a semi-
quantitative scale. The BRAF V600E expression 
was scored as percentage of positive neoplastic 
cells and intensity of immunoreactivity. The 
percentage scoring of immunoreactive (IR) 
tumor cells was as follows: 0 (0% IR cells), 
1 (1–10% IR cells), 2 (11–30% IR cells), 3 
(31–50% IR cells), and 4 ( >50%). The staining 
intensity was scored as follows: 0 (negative), 
1 (weak), 2 (moderate), and 3 (strong). A final 
score was obtained for each case by multiplying 
the percentage and the intensity score. Therefore, 
four categories for BRAF V600E expression 
were assigned: negative (score 0), low (scores 
1 and 2), and moderate (score 3 and 4) and 
high (score 6–12). The slides were assessed for 
cytoplasmic staining only.
Statistics 
The data were evaluated by means of 
bivariate analysis Chi-square using SPSS for 
Windows version 20 (SPSS, Chicago, Ill., 
USA). Independent variable were BRAF V600E 
immunoexpression and dependent variable were 
Duke’s stage CRC. The results expressed as 
p<0.05 were considered statistically significant.
RESULTS
A total of 45 cases of colorectal carcinoma 
were assessed in immunohistochemistry staining 
pattern. We selected 15 cases each Dukes’ stage 
(A, B, C) with complete archive paraffin block 
and representative tumor mass and reviewed 
Dukes’ stage from H+E slides. The clinical and 
pathological features are presented in Table 1.










 - Mean: 52.7 year
 - Standard deviation: 
12.8 year
Sex
 - Man 8 11 6 25
 - Woman 7 4 9 20
Histopathologic variant
 - Adenocarcinoma 11 10 13 34
 - Adenocarcinoma 
with mucinous 
degeneration
0 1 0 1
 - Mucinous 
adenocarcinoma
3 4 2 9
 - Signet-ring cell 
carcinoma
1 0 0 1
Grade
 - Well 11 6 8 25
 - Moderately 0 3 5 8
 - Poorly 0 1 0 1
 - Without grade 4 5 2 11
Briefly, the mean age was 52.7 years 
(Standard deviation = 12.8 year) and 25 of 
45 cases were males. Most patient 34 of 45 
cases presented with adenocarcinoma variant. 
Figure 1–4 along with photomicrographs of 
representative staining patterns.
Figure 1. Strong intensity BRAF V600E immunoexpression 
(400x). Arrow show dark brown cytoplasm (=Strong Intensity)
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BRAF V600E Immunoexpression in Dukes’ 
Stage of CRC
BRAF V600E immunoexpressions were 
assesed for cytoplasmic staining only. Twenty-
three of 45 CRCs were positive BRAF V600E 
immunoexpressions (7 cases of 45 cases with 
strongly positive, 11 cases of 45 cases with 
moderately positive, and 5 cases of 45 cases 
with weakly positive) and 22 of 45 CRCs were 
negative BRAF V600E immunoexpressions.
Chi-Square test showed that the proportion of 
positive BRAF V600E immunoexpression was 
significantly higher in Dukes’ stage C (P < 0,001). 
The results of BRAF V600E immunoexpression 
in three groups were sumarized in Table 3.
Figure 2. Moderate intensity BRAF V600E immunoexpression 
(400x). Arrow show brown cytoplasm (=Moderate Intensity)
Figure 3. Weak intensity BRAF V600E immunoexpression 
(400x). Arrow show light brown cytoplasm (=Weak Intensity)
Figure 4. Negative BRAF V600E immunoexpression (400x)
Table 2. Result of BRAF V600E immunoexpressions in 











Strongly positive 1 1 5 7
Moderately positive 0 3 8 11
Weakly positive 1 4 0 5
Negative 13 7 2 22
Total 15 15 15 45













strongly positive 1 4 13 18
Negative to weakly 
positive 14 11 2 27
Total 15 15 15 45
p value <0.001 (significant)
DISCUSSION
Activating mutations in BRAF have been 
reported in 5–15% of colorectal carcinomas 
(CRC). The most common BRAF mutation 
corresponds to a T>A transversion at position 
1799, resulting in the substitution of Valine 
by Glutamate at position 600 of the protein.13 
This mutation results in an enhanced activity 
of the kinase domain, stimulating cell division, 
cellular survival, proliferation, differentiation, 
and inhibition apoptosis.9
Affolter et al used antibody VE1 for 
immunohistochemistry to detect BRAF V600E 
mutations in CRC and there was 100% sensitivity 
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and specificity relative to pyrosequencing.12 We 
used this technique as an alternative to molecular 
methods for detecting of the BRAF V600E 
mutation.
In our study we scored BRAF V600E 
immunoexpression by multiplying the percentage 
and the intensity score and then we classified 
these score into negative immunoexpression, 
weakly positive immunoexpression, moderately 
positive immunoexpression and strongly 
positive immunoexpression. In some journals 
a tumor was considered immunopositive for 
BRAFV600E if it displayed a staining intensity 
of moderately positive or strongly positive 
irrespective of the number of tumor cells 
stained, but some journals scored by multiplying 
the percentage of positive cells with staining 
intensity.12,14,15
Interestingly, we observed BRAF mutation 
were present in 18 cases (11 cases of 45 cases 
with moderately positive immunoexpression 
and 7 cases of 45 cases with strongly positive 
immunoexpression) of all samples; while 
studies performed by Marin et al., Wilmott et 
al. categorized weakly positive BRAF V600E 
immunoexpression as negative result.15,16 The 
highest frequencies positive BRAF V600E 
immunoexpression were seen in Dukes’ stage C.
Positive BRAF V600E immunoexpression 
were more frequently seen in Dukes’ stage C 
CRC explained clearly that BRAF V600E play 
an important role in pathogenesis colorectal 
carcinoma. The Ras/Raf/MEK/ERK mitogen-
activated protein kinase (MAPK) pathway is a 
critical signal transduction pathway involved 
in many cancers, including colorectal cancer. 
The BRAF oncogene, which is immediately 
downstream of Ras in the MAPK cascade. 
The MAPK signalling cascade functions 
immediately downstream of cell surface 
receptors and cytoplasmic signalling proteins, 
relaying extracellular signals to transcriptional 
regulation of fundamental cellular functions such 
as growth, survival, proliferation, differentiation 
and migration. This pathway is deregulated in 
about 30% of all human cancers and can be 
activated by mutations in oncogenes such as 
KRAS and BRAF, or activation of upstream 
receptor tyrosine kinases such as EGFR.8,17 
Mutations in the kinase domain of the BRAF 
gene can lead to constitutive activation of the 
enzyme, resulting in dysregulated downstream 
signaling via MEK and ERK, excessive cell 
proliferation, and survival independent of 
external cellular signals.18
In this study positive BRAF V600E 
immunoexpression was more frequent in 
colorectal carcinoma Dukes’ stage C (14/15). 
This result was significant (P<0.000) using Chi-
Square test analysis. These result was similar 
with the resluts of study don by Busby et al 
which used the mismatch ligation assay (MLA) 
technique to detect the BRAF mutant tumours, 
found that four of the five BRAF mutant tumours 
were Dukes’ stage C, with the other being Dukes’ 
D, and the results were significantly more likely 
to be stage C or D, rather than A or B, than those 
without such a mutation (5/5v15/38 primary 
cancers).19
Ogino et al. studied BRAF mutation effect on 
survival and treatment efficacy in patients with 
stage III (Dukes’ stage C) colon cancer and they 
confirmed that BRAF-mutated CRC is associated 
with inferior survival in stage III (Dukes’ stage 
C) colon cancer.20 This data showed that the 
colorectal cancer with BRAF mutation have 
Dukes’stage C and poorer prognosis and lower 
response than BRAF type. Result of this study 
showed that BRAF V600E immunoexpression 
was most frequent in aggresive colon cancer. 
Therefore, Dukes stage B CRCs need BRAF 
V600E immunoexpression examination. If 
Dukes stage B CRCs had positive BRAF V600E 
immunoexpression, it can be used as a guideline 
for giving adjuvant chemotherapy.
Farin a-Sarasqueta et al. assessed the effect 
of the V600E BRAF mutation, in stage II 
(Dukes’ stage B) and stage III (Dukes’ stage 
C) colon cancer patients. The carriage of the 
mutation accounts for a significantly higher risk 
of dying of cancer-related causes, independently 
of other factors like age, sex, location of the 
tumor, MSI status, KRAS mutational status, 
differentiation grade, T stage and N stage.7
The epidermal growth factor receptor 
(EGFR), represents an important target 
for cancer treatment because its activation 
stimulates key processes involved in tumor 
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growth and progression, including proliferation, 
angiogenesis, invasion, and metastasis. EGFR 
inhibitors-monoclonal antibodies targeting 
the extracellular domain and small-molecule 
tyrosine kinase inhibitors have been extensively 
studied in metastatic colorectal cancer. The first 
EGFR monoclonal antibody to be approved 
for clinical use for metastatic colorectal cancer 
(Dukes’s stage C) has been evaluated primarily 
in combination with chemotherapy but also as 
monotherapy.21
Positive EGFR protein expression, as 
determined by immunohistochemistry, was 
initially selected as an entry criterion for studies 
evaluating EGFR inhibitors with assumption 
that sensitivity to such agents was associated 
with EGFR expression. However, a large body 
of evidence from patients who were treated with 
monoclonal antibodies for metastatic colorectal 
cancer or tyrosine kinase inhibitors for other 
solid tumors indicates that this biomarker is 
poorly associated with response to EGFR 
inhibitors in the clinical setting.21 In a recent 
study, the efficacy of antibody therapy against 
the epidermal growth factor receptor for wild-
type–KRAS tumors appeared to be restricted to 
wild-type–BRAF tumors.22 Immunoexpression 
of BRAF V600E can be used to know the efficacy 
of antibody therapy against the epidermal growth 
factor receptor.
Signaling through the EGFR and its 
downstream pathways presents numerous 
potential targets for treating patients with 
cancer. Many clinical trials are underway 
using agents MAP kinase signaling, including 
BRAF.9 The clinical development of BRAF 
inhibitors in colorectal cancer carrying the 
BRAF V600E mutation, the enriched population, 
will be challenging due to the low BRAF V600E 
mutation rate in this tumour type.8 Efficacious 
targeted therapy would expand the indications 
for BRAF gene testing.9 Immunohistochemical 
detection of BRAF V600E mutation is a fast, 
inexpensive technique and seems to have a very 
good specificity.16 As immunohistochemistry is 
cheaper and results are easily obtained within 
48 hours, it could be used as the first step 
for BRAF mutational status.23 BRAF V600E 
immunohistochemistry could be used as first 
screening for efficacy of BRAF V600E targeted 
therapy.
CONCLUSION
The immunoexpression of BRAF V600E is 
mostly present in Dukes’ stage C CRC.
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